Centivax

We are excited to announce our partnership with Emery Pharma. "Having a trusted partner to conduct rigorous in vitro development of our batch release potency assay is crucial for the immediate need of initiating clinical trials of our first universal vaccine candidate." Jacob Glanville, CEO.

Dr. Glanville discusses "Why we need a broad spectrum influenza vaccine" with Radio New Zealand. #influenza #InfluenzaAwareness #Centivax #vaccine #immunology #publichealth #biotech #researchanddevelopment #scientist #QuadDemic

We are honored to join the Coalition to Stop Flu as one of its newest members. Read more here: https://lnkd.in/enikzCjs

The Coalition is excited to welcome Blueprint Biosecurity and Centivax as its newest members. Blueprint Biosecurity is a nonprofit dedicated to reducing the threat of airborne disease. Centivax is a leader in universal vaccine development, working to end the threat of seasonal and pandemic influenza through its universal flu vaccine, CentiFlu. Read more ??

The Science of Innovation: Jake Glanville on Revolutionizing Biotech and Pandemic Prevention. In this episode ofSync’d Up, host Andreas Dankelmann sits down with Jake Glanville, founder and CEO of Centivax, to discuss his groundbreaking work in biotech. Known for his contributions to universal vaccines and featured in Netflix’sHow to Prevent a Pandemic, Jake shares his journey from corporate pharma to entrepreneurship. He reveals the challenges of scaling biotech ventures, the leadership strategies that drive innovation, and how he envisions a world where pandemics are a thing of the past. https://lnkd.in/grhGWABe #influenza #InfluenzaAwareness #Centivax #vaccine #immunology #publichealth #biotech #researchanddevelopment #scientist #QuadDemic

A deadly strain of bird flu has been detected in dairy cows for the first time. Dr. Jacob Glanville, CEO of biotech firm Centivax, joins "The Daily Report" to explain why this discovery is concerning and how big a risk it poses to public health.

Centivax's Chief Executive Officer,?Jacob Glanville, said, "We are thrilled to announce BioCina as our Master Cell Bank manufacturing partner for the first phase of manufacturing our universal influenza vaccine. BioCina's exemplary expertise and track record in mRNA/LNP MCB, combined with their state-of-the-art facilities, aligns perfectly with Centivax's commitment to innovation and quality. This partnership enables us to leverage BioCina's expertise to ensure the highest standards of vaccine production. Together, we're taking a significant step forward in bringing our universal influenza vaccine to market, with the goal of providing broad, lasting protection against the disease on a global scale."